Acasti will acquire Grace's 'pipeline of rare and orphan disease programs, including 3 clinical stage assets that have received Orphan Drug Designation from the US Food & Drug Administration,' the company said.from Top Business News- News18.com https://ift.tt/3tA8cZu
No comments:
Post a Comment